COVID‐19 in vaccinated versus unvaccinated hematologic malignancy patients
Catherine DeVoe(University of California, San Francisco), Monica Fung(University of California, San Francisco), Dayana Shariff(University of California, San Francisco), Jennifer M. Babik(University of California, San Francisco), Deborah S. Yokoe(Brigham and Women's Hospital), Charles Y. Chiu(University of California, San Francisco), Peter Chin‐Hong(University of California, San Francisco), Steve Miller(University of California, San Francisco), Shagun Arora(University of California, San Francisco), Venice Servellita(University of California, San Francisco), Charles Langelier(University of California, San Francisco), Shraddha Pandey(University of California, San Francisco), Timothy J. Henrich(University of California, San Francisco)
Cited by 6
Related Papers
CRISPR–Cas12-based detection of SARS-CoV-2
|Nature Biotechnology|2020|2.8k
Actionable Diagnosis of Neuroleptospirosis by Next-Generation Sequencing
|New England Journal of Medicine|2014|1k
COVID-19 in Immunocompromised Hosts: What We Know So Far
|Clinical Infectious Diseases|2020|568
Strategies to Prevent Catheter-Associated Urinary Tract Infections in Acute Care Hospitals: 2014 Update
|Infection Control and Hospital Epidemiology|2014|520